This report provides comprehensive information on the therapeutic development for Vasculitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vasculitis and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Vasculitis Overview
- Therapeutics Development
- Pipeline Products for Vasculitis - Overview
- Pipeline Products for Vasculitis - Comparative Analysis
- Vasculitis - Therapeutics under Development by Companies
- Vasculitis - Therapeutics under Investigation by Universities/Institutes
- Vasculitis Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Vasculitis - Products under Development by Companies
- Vasculitis - Products under Investigation by Universities/Institutes
- Vasculitis - Companies Involved in Therapeutics Development
- AnGes MG, Inc.
- ChemoCentryx, Inc.
- Cipla Ltd.
- Coherus BioSciences, Inc.
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Hemostemix Ltd
- Johnson & Johnson
- K-Stemcell Co., Ltd.
- Panacea Biotec Limited
- Pfizer Inc.
- Sandoz International GmbH
- Teijin Pharma Limited
For more information about this drug pipelines visit http://www.researchandmarkets.com/research/wjsnvc/vasculitis